Drug Trial Radar · NCT03082755
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: May 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Jul 1, 2017
Primary completion
Aug 31, 2022
Study completion Mar 31, 2023
Sponsor
- Lead sponsor
- University of Texas at AustinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Mar 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces restless legs syndrome behaviors, and reduces antipsychotic medications.
Conditions
- Alzheimer Disease
Interventions
Gabapentin EnacarbilDrug
1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
Placebo Oral TabletDrug
1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Direct ObservationTime frame: Change from baseline at 2 and 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Texas at Austin
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.